|Satraplatin (Code C1493)|
|Terms & Properties|
Preferred Name: Satraplatin
Definition: An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.
NCI-GLOSS Definition: A substance being studied in the treatment of prostate and other types of cancer. It contains the metal platinum and may kill cancer cells by damaging their DNA and stopping them from dividing. It is a type of alkylating agent.
Display Name: Satraplatin
NCI Metathesaurus Link: C1142934 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||129580-63-8 (see NLM ChemIDplus info)|
|FDA UNII Code||8D7B37T28G|
|PDQ Closed Trial Search ID||42141|
|PDQ Open Trial Search ID||42141 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|